SMMT · Categories · Form 4

SMMT - SEC Form 4 insider transactions

Summit Therapeutics Inc. (SMMT) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for SMMT

• 148d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Director Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Director Xia Yu

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Director Huber Jeff

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Director Ronaghi Mostafa

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Director Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 154d
  SEC Form 4 filed by Director Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 229d
  Chief Accounting Officer Anand Bhaskar was granted 26,680 shares, increasing direct ownership by 20% to 159,751 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 229d
  COO and CFO Soni Manmeet Singh was granted 53,361 shares, increasing direct ownership by 2% to 3,073,603 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 263d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 372d
  Co-Chief Executive Officer Zanganeh Mahkam exercised 74,545 shares at a strike of $2.64 (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 372d
  Co-Chief Executive Officer Duggan Robert W exercised 74,545 shares at a strike of $2.64, increasing direct ownership by 0.01% to 555,754,696 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 404d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 404d
  SEC Form 4 filed by COO and CFO Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 404d
  SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 404d
  SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 426d
  Co-Chief Executive Officer Zanganeh Mahkam exercised 3,985,055 in-the-money shares at a strike of $1.58 (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 426d
  Co-Chief Executive Officer Duggan Robert W exercised 3,985,055 in-the-money shares at a strike of $1.58, increasing direct ownership by 0.72% to 555,680,151 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 511d
  SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Co-Chief Executive Officer Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Co-Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Director Huber Jeff

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Director Xia Yu

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Director Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Director Ronaghi Mostafa

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Director Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 519d
  SEC Form 4 filed by Director Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 602d
  SEC Form 4 filed by Director Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 614d
  Co-Chief Executive Officer Zanganeh Mahkam exercised 315,681 in-the-money shares at a strike of $1.58 (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 634d
  Co-Chief Executive Officer Zanganeh Mahkam was granted 44,052 shares (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 634d
  Co-Chief Executive Officer Duggan Robert W was granted 3,325,991 shares, increasing direct ownership by 0.61% to 551,695,096 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 634d
  Director Huber Jeff was granted 44,052 shares (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 634d
  COO and CFO Soni Manmeet Singh was granted 44,052 shares, increasing direct ownership by 1% to 3,020,242 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 634d
  Chief Accounting Officer Anand Bhaskar was granted 22,026 shares, increasing direct ownership by 20% to 131,426 units (SEC Form 4)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 655d
  SEC Form 4 filed by COO and CFO Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 655d
  SEC Form 4 filed by Chief Executive Officer Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 712d
  SEC Form 4 filed by Director Huber Jeff

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 785d
  SEC Form 4 filed by Ronaghi Mostafa

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 796d
  SEC Form 4 filed by Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 796d
  SEC Form 4 filed by Anand Bhaskar

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 887d
  SEC Form 4 filed by Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 887d
  SEC Form 4 filed by Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 887d
  SEC Form 4 filed by Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 887d
  SEC Form 4 filed by Mahatme Ujwala

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 887d
  SEC Form 4 filed by Xia Yu

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 887d
  SEC Form 4 filed by Duggan Robert W

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 967d
  SEC Form 4 filed by Zanganeh Mahkam

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1184d
  SEC Form 4: Zanganeh Mahkam bought $24,703,396 worth of shares (23,527,044 units at $1.05) (Amendment)

  4/A - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1189d
  SEC Form 4: Zanganeh Mahkam bought $24,703,396 worth of shares (23,527,044 units at $1.05), increasing direct ownership by 215% to 23,395,269 units

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1189d
  SEC Form 4: Dhingra Ankur bought $206,180 worth of shares (196,362 units at $1.05)

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1189d
  SEC Form 4: Dhingra Ankur bought $36,554 worth of shares (37,685 units at $0.97), increasing direct ownership by 49% to 39,527 units (Amendment)

  4/A - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1189d
  SEC Form 4: Duggan Robert W bought $395,314,374 worth of shares (376,489,880 units at $1.05), increasing direct ownership by 214% to 552,354,161 units

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1251d
  SEC Form 4 filed by Booth Robert F.

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1251d
  SEC Form 4 filed by Cesano Alessandra

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1251d
  SEC Form 4 filed by Mahatme Ujwala

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1251d
  SEC Form 4 filed by Clark Kenneth A

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1251d
  SEC Form 4 filed by Soni Manmeet Singh

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)
• 1278d
  SEC Form 4: Zanganeh Mahkam acquired 373,857 shares, increasing direct ownership by 4% to 10,930,849 units

  4 - Summit Therapeutics Inc. (0001599298) (Issuer)

Other SMMT categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends